URGN insider transaction filings
UroGen Pharma Ltd. — 40 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-10. Screen URGN transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-10 | 4 | Schoenberg Mark — Chief Medical Officer | Sale (S): 10,000 @ $40 | EDGAR |
| 2026-06-24 | 4 | Schoenberg Mark — Chief Medical Officer | Sale (S): 10,000 @ $35.01 | EDGAR |
| 2026-06-24 | 4 | Wildman Daniel George — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Robinson James A. Jr. — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Holden Stuart — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | WEN LEANA — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Belldegrun Arie — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | BUTITTA CYNTHIA M — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Schoenberg Mark — Chief Medical Officer | Option exercise (M): 10,000 · Sale (S): 5,222 @ $27.30 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Robinson James A. Jr. — Director | Option exercise (M): 2,000 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Schoenberg Mark — Chief Medical Officer | Sale (S): 10,000 @ $30 | EDGAR |
| 2026-02-27 | 4 | Robinson James A. Jr. — Director | Option exercise (M): 2,000 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Barrett Elizabeth A. — Chief Executive Officer | Grant/award (A): 153,195 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Smith Jason Drew — General Counsel | Option exercise (M): 5,500 · Sale (S): 2,654 @ $19.69 · Option exercise (M): 3,333 · Sale (S): 1,608 @ $19.69 · Option exercise (M): 6,667 · Sale (S): 3,217 @ $19.69 · +4 more | EDGAR |
| 2026-02-04 | 4 | Schoenberg Mark — Chief Medical Officer | Sale (S): 1,844 @ $19.69 · Sale (S): 1,843 @ $19.69 · Sale (S): 3,686 @ $19.69 | EDGAR |
| 2026-02-03 | 4 | Schoenberg Mark — Chief Medical Officer | Option exercise (M): 3,333 · Option exercise (M): 6,666 · Option exercise (M): 3,334 · Option exercise (M): 3,333 (derivative) @ $0 · Option exercise (M): 6,666 (derivative) @ $0 · Option exercise (M): 3,334 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-03 | 4 | Degnan Chris — Chief Financial Officer | Grant/award (A): 32,609 (derivative) @ $0 | EDGAR |
| 2025-12-01 | 4 | Holden Stuart — Director | Option exercise (M): 2,000 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2025-12-01 | 4 | Robinson James A. Jr. — Director | Option exercise (M): 2,000 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2025-12-01 | 4 | WEN LEANA — Director | Option exercise (M): 2,000 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2025-12-01 | 4 | Wildman Daniel George — Director | Option exercise (M): 2,000 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2025-12-01 | 4 | BUTITTA CYNTHIA M — Director | Option exercise (M): 2,000 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2025-11-20 | 4 | Schoenberg Mark — Chief Medical Officer | Sale (S): 10,000 @ $25 | EDGAR |
| 2025-10-09 | 4 | Degnan Chris — Chief Financial Officer | Option exercise (M): 4,483 · Sale (S): 2,203 @ $16.85 · Option exercise (M): 4,483 (derivative) @ $0 | EDGAR |
| 2025-09-09 | 4 | Schoenberg Mark — Chief Medical Officer | Option exercise (M): 1,667 · Sale (S): 871 @ $19.11 · Option exercise (M): 1,667 (derivative) @ $0 | EDGAR |
| 2025-09-09 | 4 | Smith Jason Drew — General Counsel | Option exercise (M): 3,333 · Sale (S): 1,520 @ $19.11 · Option exercise (M): 3,333 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | Wildman Daniel George — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | Robinson James A. Jr. — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | Holden Stuart — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | WEN LEANA — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | Belldegrun Arie — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | BUTITTA CYNTHIA M — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-08-13 | 4 | Schoenberg Mark — Chief Medical Officer | Sale (S): 10,000 @ $17.69 | EDGAR |
| 2025-07-30 | 4 | Barrett Elizabeth A. — Chief Executive Officer | Grant/award (A): 87,615 (derivative) @ $0 | EDGAR |
| 2025-07-30 | 4 | Smith Jason Drew — General Counsel | Option exercise (M): 16,500 · Sale (S): 7,522 @ $19.14 | EDGAR |
| 2025-07-30 | 4 | Schoenberg Mark — Chief Medical Officer | Option exercise (M): 10,000 · Sale (S): 5,149 @ $19.14 | EDGAR |
| 2025-06-11 | 4 | Schoenberg Mark — Chief Medical Officer | Option exercise (M): 10,000 · Sale (S): 5,162 @ $7.37 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Schoenberg Mark — Chief Medical Officer | Option exercise (M): 1,334 · Sale (S): 759 @ $11.14 · Option exercise (M): 3,333 · Sale (S): 1,896 @ $11.14 · Option exercise (M): 3,333 · Sale (S): 1,896 @ $11.14 · +4 more | EDGAR |
| 2025-02-04 | 4 | Smith Jason Drew — General Counsel | Option exercise (M): 2,500 · Sale (S): 1,258 @ $11.14 · Option exercise (M): 6,667 · Sale (S): 3,354 @ $11.14 · Option exercise (M): 5,500 · Sale (S): 2,767 @ $11.14 · +4 more | EDGAR |
| 2025-02-04 | 4 | Barrett Elizabeth A. — Chief Executive Officer | Grant/award (A): 96,377 (derivative) @ $0 | EDGAR |
Recent 8-K events — UroGen Pharma Ltd.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-20 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=URGN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →